Doomsday AMR scenarios lurk: What's FDA, others doing?
This article was originally published in Scrip
With antimicrobial-resistance (AMR) doomsday scenarios coming fast and furious in recent months – with one even projecting as many as 10 million people worldwide could be sickened by "superbug" infections by 2050 – one wonders why with all the dire warnings the problem has not yet been solved and why it's been such a tough nut to crack.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.